Parabilis Medicines, Inc.
PBLSNasdaq
$29.55
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↓ -6.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines. Our principal executive offices are located in Cambridge, MA.
- CEO
- Mathai Mammen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 145
- Headquarters
- Massachusetts
- Website
- parabilismed.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 15, 2026
Jun 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | SEBULSKY ALAN | Buy | 5,000 | $26.00 | $129,989.00 | filing |
| 2026-06-15 | SEBULSKY ALAN | Buy | 4,065 | $27.10 | $110,146.46 | filing |
| 2026-06-12 | SEBULSKY ALAN | Buy | 8,435 | $27.67 | $233,393.08 | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, LLC | Buy | 19,728,353 | $20.00 | $394.6M | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, LLC | Buy | 1,460,397 | $20.00 | $29.2M | filing |
| 2026-06-11 | Levy Guy | Buy | 375,000 | $20.00 | $7.5M | filing |
| 2026-06-11 | Levy Guy | C | 527,070 | $9.48 | $5.0M | filing |
| 2026-06-11 | Levy Guy | Buy | 125,000 | $20.00 | $2.5M | filing |
| 2026-06-11 | SEBULSKY ALAN | Buy | 12,500 | $20.00 | $250,000.00 | filing |
| 2026-06-11 | Flynn James E | C | 149,238 | — | — | filing |
| 2026-06-11 | Flynn James E | C | 149,238 | — | — | filing |
| 2026-06-11 | Flynn James E | C | 260,992 | — | — | filing |
| 2026-06-11 | Flynn James E | C | 260,992 | — | — | filing |
| 2026-06-11 | Flynn James E | C | 407,132 | — | — | filing |
| 2026-06-11 | Flynn James E | C | 407,132 | — | — | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, LLC | C | 6,556,740 | — | — | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, LLC | C | 1,187,881 | — | — | filing |
| 2026-06-11 | FITZGERALD EDWARD M | C | 5,539 | — | — | filing |
| 2026-06-11 | FITZGERALD EDWARD M | C | 3,878 | — | — | filing |
| 2026-06-11 | FITZGERALD EDWARD M | C | 5,271 | — | — | filing |
| 2026-06-11 | Borisy Alexis | C | 105,414 | — | — | filing |
| 2026-06-11 | Flynn James E | C | 122,990 | — | — | filing |
| 2026-06-11 | Flynn James E | C | 122,990 | — | — | filing |
Latest 23 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.